CMPS is trading at $13.96 (8.7% up) after announcing successful Phase 3 results for its COMP360 psilocybin therapy in treatment-resistant depression, achieving the primary endpoint in two trials.
- The COMP006 study reported highly statistically significant and clinically meaningful symptom reduction, meeting key clinical goals.
- The positive data reinforces expectations for a future FDA filing and strengthens the long-term bullish thesis for the company's lead candidate.